These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 34560137

  • 1. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
    Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, Ji B, Green Y, Gonzalez-Rivera T, Bass D, Gilbride J, Tang CH, Roth DA.
    Kidney Int; 2022 Feb; 101(2):403-413. PubMed ID: 34560137
    [Abstract] [Full Text] [Related]

  • 2. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
    Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA.
    N Engl J Med; 2020 Sep 17; 383(12):1117-1128. PubMed ID: 32937045
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
    Yu X, Chen N, Xue J, Mok CC, Bae SC, Peng X, Chen W, Ren H, Li X, Noppakun K, Gilbride JA, Green Y, Ji B, Liu C, Madan A, Okily M, Tang CH, Roth DA.
    Am J Kidney Dis; 2023 Mar 17; 81(3):294-306.e1. PubMed ID: 36058429
    [Abstract] [Full Text] [Related]

  • 4. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
    Furie R, Rovin BH, Houssiau F, Contreras G, Teng YKO, Curtis P, Green Y, Okily M, Madan A, Roth DA.
    Clin J Am Soc Nephrol; 2022 Nov 17; 17(11):1620-1630. PubMed ID: 36302567
    [Abstract] [Full Text] [Related]

  • 5. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
    Gatto M, Saccon F, Andreoli L, Bartoloni E, Benvenuti F, Bortoluzzi A, Bozzolo E, Brunetta E, Canti V, Cardinaletti P, Ceccarelli F, Ciccia F, Conti F, De Marchi G, de Paulis A, De Vita S, Emmi G, Faggioli P, Fasano S, Fredi M, Gabrielli A, Gasparotto M, Gerli R, Gerosa M, Govoni M, Gremese E, Laria A, Larosa M, Mosca M, Orsolini G, Pazzola G, Petricca L, Ramirez GA, Regola F, Rossi FW, Rossini M, Salvarani C, Scarpato S, Tani C, Tincani A, Ubiali T, Urban ML, Zen M, Doria A, Iaccarino L.
    J Autoimmun; 2021 Nov 17; 124():102729. PubMed ID: 34600347
    [Abstract] [Full Text] [Related]

  • 6. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM, BLISS-52 and -76 Study Groups.
    Lupus; 2013 Jan 17; 22(1):63-72. PubMed ID: 23263865
    [Abstract] [Full Text] [Related]

  • 7. BLISS-LN trial revisited: function matters.
    Gleeson S, Lightstone L.
    Kidney Int; 2022 Feb 17; 101(2):224-226. PubMed ID: 35065691
    [Abstract] [Full Text] [Related]

  • 8. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.
    Liu T, Neuner R, Thompson A, Pottackal G, Petullo D, Liu J, Nikolov N, Sahajwalla C, Doddapaneni S, Chen J.
    Lupus; 2022 Apr 17; 31(4):424-432. PubMed ID: 35238725
    [Abstract] [Full Text] [Related]

  • 9. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient).
    Binda V, Trezzi B, Del Papa N, Beretta L, Frontini G, Porata G, Fabbrini P, Pozzi MR, Messa P, Sinico RA, Moroni G.
    J Nephrol; 2020 Oct 17; 33(5):1019-1025. PubMed ID: 32002799
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.
    Fontana F, Alfano G, Leonelli M, Cerami C, Ligabue G, Spinella A, Citriniti G, Manzini CU, Ferri C, Cappelli G.
    BMC Nephrol; 2018 Oct 20; 19(1):276. PubMed ID: 30342482
    [Abstract] [Full Text] [Related]

  • 11. MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT.
    Sada K, Kurita N, Noma H, Matsuki T, Quasny H, Levy RA, Jones-Leone AR, Gairy K, Yajima N.
    Lupus Sci Med; 2022 Sep 20; 9(1):. PubMed ID: 37017254
    [Abstract] [Full Text] [Related]

  • 12. Urine proteomic insights from the belimumab in lupus nephritis trial.
    Weeding E, Fava A, Mohan C, Magder L, Goldman D, Petri M.
    Lupus Sci Med; 2022 Sep 20; 9(1):. PubMed ID: 36167482
    [Abstract] [Full Text] [Related]

  • 13. The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States.
    Mandrik O, Fotheringham J, Ren S, Tice JA, Chapman RH, Stevenson MD, Pearson SD, Herron-Smith S, Agboola F, Thokala P.
    Clin J Am Soc Nephrol; 2022 Mar 20; 17(3):385-394. PubMed ID: 35115304
    [Abstract] [Full Text] [Related]

  • 14. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman.
    Fließer EE, Korsten P, Koziolek MJ, Niewold TB, Patschan D, Müller GA, Patschan SA.
    Lupus; 2013 Dec 20; 22(14):1523-5. PubMed ID: 24014569
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy.
    Liu D, Zhou Q, Wang D, Qu Y, Guo Q, Wen J, Yu Q, Ai J.
    Lupus; 2022 Oct 20; 31(12):1456-1467. PubMed ID: 35960182
    [Abstract] [Full Text] [Related]

  • 16. Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.
    Margiotta DPE, Basta F, Batani V, Afeltra A.
    BMC Nephrol; 2018 Mar 07; 19(1):54. PubMed ID: 29514612
    [Abstract] [Full Text] [Related]

  • 17. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Staveri C, Karokis D, Liossis SC.
    Semin Arthritis Rheum; 2017 Jun 07; 46(6):788-790. PubMed ID: 27793432
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review.
    Zhang C, Zeng M, Ge Y, Liu K, Xing C, Mao H.
    Front Immunol; 2022 Jun 07; 13():977377. PubMed ID: 36172377
    [Abstract] [Full Text] [Related]

  • 19. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
    Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M.
    Arthritis Rheumatol; 2021 Jan 07; 73(1):121-131. PubMed ID: 32755035
    [Abstract] [Full Text] [Related]

  • 20. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.